1 / 12

Syndromes of Dementia and Movement Disorders Market

The treatment for syndromes of dementia and movement disorders market is witnessing significant growth due to increasing R&D investments in drug discovery and developments. In addition, increasing prevalence of neurodegenerative disorders and rising awareness about mental disorders are also driving the growth of the market. However, most of the drugs fail in Phase III due to lack of sufficient knowledge about the mechanisms of the brain and the unknown causes of the disease. In addition, lack of comprehensive therapeutic management, strict regulations, and time-consuming drug approval process inhibit the growth of the market. The global treatment for syndromes of dementia and movement disorders market is anticipated to grow from an estimated USD 12,859.8 million in 2014 to USD 21,154.8 million in 2020 at a CAGR of 8.6% during the forecast period.

addiethomes
Download Presentation

Syndromes of Dementia and Movement Disorders Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:Asiato HighestGrowthby2020 Witness PersistenceMarketResearch GlobalTreatmentforSyndromesof DementiaandMovementDisordersMarket isExpectedtoGrowataCAGRof8.6%from 2014to2020:PersistenceMarketResearch 1 PersistenceMarketResearch

  2. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 PersistenceMarketResearchReleasedNewMarketReport“GlobalMarketStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitnessHighestGrowthby2020,”theglobal treatmentforsyndromesofdementiaandmovementdisordersmarketwasvaluedatUSD12,859.8 millionin2014andisexpectedtogrowataCAGRof8.6%from2014to2020,toreachanestimated valueofUSD21,154.8millionin2020. Thetreatmentforsyndromesofdementiaandmovementdisordersmarketiswitnessingsignificant growthduetoincreasingR&Dinvestmentsindrugdiscoveryanddevelopments.Inaddition,increasing prevalenceofneurodegenerativedisordersandrisingawarenessaboutmentaldisordersarealsodriving thegrowthofthemarket.However,mostofthedrugsfailinPhaseIIIduetolackofsufficientknowledge aboutthemechanismsofthebrainandtheunknowncausesofthedisease.Inaddition,lackof comprehensivetherapeuticmanagement,strictregulations,andtime-consumingdrugapprovalprocess inhibitthegrowthofthemarket.Theglobaltreatmentforsyndromesofdementiaandmovementdisorders marketisanticipatedtogrowfromanestimatedUSD12,859.8millionin2014toUSD21,154.8millionin 2020ataCAGRof8.6%duringtheforecastperiod. InNorthAmerica,growingagingpopulationandrisingincidenceofneurodegenerativediseasearedriving theuseoftreatmentforsyndromesofdementiaandmovementdisordersinthemarket.Inaddition,lack ofpropermedicationisalsofuellingthegrowthoftreatmentsforsyndromesofdementiaandmovement disordersmarket. InEurope,thetreatmentforsyndromesofdementiaandmovementdisordersmarketisdrivenbyrising incidenceofmentaldisorderrelateddiseaseandgrowingagingpopulation.Ontheotherhand,various awarenessprogramswerelaunchedbypublicandprivatehealthinstitutionstocontroldementiaand movementdisorders,whichwouldincreasetheuseofdementiaandmovementdisorderdrugsinthe region. However,inAsiathegrowthfortreatmentforsyndromesofdementiaandmovementdisordersismuch higherthandevelopedcountriesduetowideninghealthinsurancepenetration,andlargepopulationbase. 2 PersistenceMarketResearch

  3. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 F.Hoffmann-LaRoche,Ltd.,NovartisAG,Merck&Co.,Inc.,SanofiS.A.,ValeantPharmaceutical International,Inc.,AstraZenecaGmbHandPfizer,Inc.aresomeofthemajorplayersoftreatmentforsyndromesofdementiaandmovementdisordersmarket. BrowsethefullGlobalMarketStudyonTreatmentforSyndromesofDementiaandMovement Disorders: Asia to Witness Highest Growth by 2020 report at http://www.persistencemarketresearch.com/market-research/treatment-syndromes-dementia-movement- disorders-market.asp Thetreatmentforsyndromesofdementiaandmovementdisordersmarketissegmentedas follows: Treatmentforsyndromesofdementiaandmovementdisordersmarket,bydrugsusedtotreat progressivedementia •Diseasesbasedtherapeuticsunderprogressivedementia •Drugsforprogressivedementia Treatmentforsyndromesofdementiaandmovementdisordersmarket,bydrugsusedtotreat progressivedementiawithotherneurologicalabnormalities •Diseasebasedtherapeuticsunderprogressivedementiawithotherneurologicalabnormalities •Drugsforprogressivedementiawithotherneurologicalabnormalities Treatmentforsyndromesofdementiaandmovementdisordersmarket,bydrugsusedtotreat movementdisorders •Diseasesbasedtherapeuticsundermovementdisorders •Drugsformovementdisorders Treatmentforsyndromesofdementiaandmovementdisordersmarket,bygeography 3 PersistenceMarketResearch

  4. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 •NorthAmerica •Europe •Asia •RestoftheWorld(RoW) MarketHistory: Globally,thetreatmentforsyndromesofdementiaandmovementdisordersmarketiswitnessing significantgrowthduetoincreasingprevalenceofneurodegenerativediseases.Inaddition,increasing R&Dinvestmentindrugdeliveryanddevelopmentandrisingawarenessofmentaldisordersarealso fuelingthegrowthofthemarket.However,strictregulatoryrequirementsandlongapprovaltimefordrugs hampersgrowthoftheglobaltreatmentforsyndromesofdementiaandmovementdisordersmarket. Theglobaltreatmentforsyndromesofdementiaandmovementdisordersmarketisanticipatedtogrow fromanestimatedUSD12,859.8millionin2014toUSD21,154.8millionin2020ataCAGRof8.6% duringtheforecastperiod.NorthAmericaisthelargestregionfortreatmentforsyndromesofdementia andmovementdisordersmarketandAsiaisthefastestgrowingregion.Inaddition,progressivedementia isthemostpopularandfastestgrowingsegmentinthismarket. Frontotemporaldementia,Alzheimer’sdisease,andLewybodydementiaaresomeofthetypesof progressivedementia.TheAlzheimer’sdiseasetreatmentmarketisanticipatedtogrowfromanestimated USD4,755.2millionin2014toUSD8,208.2millionin2020,growingataCAGRof9.5%duringtheforecastperiod. 4 PersistenceMarketResearch

  5. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementia HighestGrowthby2020 and Movement Disorders : Asia to Witness TableofContent Chapter1Preface 1.1ReportDescription 1.2ResearchMethodology 1.3Assumptions Chapter2MarketSynopsis Chapter3Porter’sFiveForcesAnalysis 3.1BargainingPowerofSuppliers 3.2BargainingPowerofBuyers 3.3ThreatofNewEntrants 3.4ThreatofSubstitutes 3.5IntensityofRivalry Chapter4IndustryOverview 4.1MarketDefinition 5 PersistenceMarketResearch

  6. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 4.2MarketDrivers 4.2.1Increasingprevalenceofneurodegenerativediseases 4.2.2Risingawarenessaboutmentaldiseases 4.2.3IncreasingR&Dinvestmentsindrugdiscoveryanddevelopments 4.3ImpactAnalysisofMarketDrivers 4.4MarketRestraints 4.4.1Strictregulatoryrequirementsandlongapprovaltimefordrugs 4.4.2Lackofcomprehensivetherapeuticmanagementofdementiaandmovementdisorders 4.5ImpactAnalysisofMarketRestraints 4.6MarketTrend 4.6.1Risingnumberofcollaborationsandpartnershipswouldleadtoriseinresearchanddiscoveryofdementiaandmovementdisorderdrugs Chapter5GlobalMarketSizeandForecast Chapter6MarketSizeandForecastbyDrugsUsedtoTreatProgressiveDementia 6.1DiseasesBasedTherapeuticsUnderProgressiveDementia 6.2DrugsforProgressiveDementia Chapter7MarketSizeandForecastbyDrugsUsedtoTreatProgressiveDementiawithOther NeurologicalAbnormalities 7.1DiseasesBasedTherapeuticsUnderProgressiveDementiawithOtherNeurologicalAbnormalities 7.2DrugsforProgressiveDementia Chapter8MarketSizeandForecastbyDrugsUsedtoTreatMovementDisorderSyndrome 8.1DiseasesBasedTherapeuticsUnderMovementDisorderSyndrome 8.2DrugsforMovementDisorderSyndrome Chapter9MarketSizeandForecastbyGeography 9.1NorthAmerica 9.2Europe 9.3Asia 6 PersistenceMarketResearch

  7. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementia HighestGrowthby2020 and Movement Disorders : Asia to Witness Chapter10CompetitiveScenario 10.1CompetitiveBenchmarking Chapter11CompanyProfiles 11.1F.Hoffmann-LaRoche,Ltd. 11.1.1Companyoverview 11.1.2Productsandservices 11.1.3Financialperformance 11.1.4Keydevelopments 11.2Baxter 11.2.1Companyoverview 11.2.2Productsandservices 11.2.3Financialperformance 11.2.4Keydevelopment 11.3NovartisAG 11.3.1Companyoverview 11.3.2Productsandservices 11.3.3Financialperformance 11.3.4Keydevelopments 11.4Merck&Co.,Inc. 11.4.1Companyoverview 11.4.2Productsandservices 11.4.3Financialperformance 11.4.4Keydevelopments 11.5Sanofi 11.5.1Companyoverview 11.5.2Productsandservices 11.5.3Financialperformance 11.5.4Keydevelopments 11.6Pfizer,Inc. 11.6.1Companyoverview 11.6.2Productsandservices 11.6.3Financialperformance 7 PersistenceMarketResearch

  8. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovement HighestGrowthby2020 Disorders : Asia to Witness 11.6.4Keydevelopments 11.7ValeantPharmaceuticalsInternational,Inc. 11.7.1Companyoverviews 11.7.2Productsandservices 11.7.3Financialperformance 11.7.4Keydevelopments 11.8AstraZenecaGmbH 11.8.1Companyoverview 11.8.2Productsandservices 11.8.3Financialperformance 11.8.4Keydevelopments 11.9AbbottLaboratories,Inc. 11.9.1Companyoverview 11.9.2Productsandservices 11.9.3Financialperformance 11.9.4Keydevelopments 11.10Bristol-MyersSquibbCompany 11.10.1Companyoverview 11.10.2Productsandservices 11.10.3Financialperformance 11.10.4Keydevelopments ListofTables TABLE1Marketsnapshot:Treatmentforsyndromesofdementiaandmovementdisordersmarket,2014 and2020 TABLE2Driversforglobaltreatmentforsyndromeofdementiaandmovementdisordersmarket:Impact analysis TABLE3Estimatedaveragetimelinesforclinicaltrialapprovalinvariouscountries TABLE4Restraintsforglobaltreatmentforsyndromesofdementiaandmovementdisordersmarket: Impactanalysis TABLE5Majorcollaborationsandpartnershipsbydementiaandmovementdisordertreatment companies(2011–2013) 8 PersistenceMarketResearch

  9. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 TABLE6Globaltreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,byregion, 2010–2013(USDmillion) TABLE7Globaltreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,byregion, 2014–2020(USDmillion) TABLE8Globaltreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,by segment,2010–2013(USDmillion) TABLE9Globaltreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,by segment,2014–2020(USDmillion) TABLE10Globalprogressivedementiatherapeuticmarketsize,bydisease,2010–2013(USDmillion) TABLE11Globalprogressivedementiatherapeuticmarketsize,bydisease,2014–2020(USDmillion) TABLE12Globalprogressivedementiamarketsize,bydrugcategory,2010–2013(USDmillion) TABLE13Globalprogressivedementiamarketsize,bydrugcategory,2014–2020(USDmillion) TABLE14Globalprogressivedementiawithotherneurologicalabnormalitiestherapeuticsmarketsize,by disease,2010–2013(USDmillion) TABLE15Globalprogressivedementiawithotherneurologicalabnormalitiestherapeuticmarketsize,by disease,2014–2020(USDmillion) TABLE16Globalprogressivedementiawithotherneurologicalabnormalitiesmarketsize,bydrug category,2010–2013(USDmillion) TABLE17Globalprogressivedementiawithotherneurologicalabnormalitiesmarketsize,bydrug category,2014–2020(USDmillion) TABLE18Globalmovementdisordersyndrometherapeuticsmarketsize,bydisease,2010–2013(USD million) TABLE19Globalmovementdisordersyndrometherapeuticsmarketsize,bydisease,2014–2020(USD million) TABLE20Globalmovementdisordersmarketsize,bydrugcategory,2010–2013(USDmillion) TABLE21Globalmovementdisordermarketsize,bydrugcategory,2014–2020(USDmillion) TABLE22TheNorthAmericantreatmentforsyndromesofdementiaandmovementdisordersmarket size,bycountry,2010–2013(USDmillion) TABLE23TheNorthAmericantreatmentforsyndromesofdementiaandmovementdisordersmarket size,bycountry,2014–2020(USDmillion) TABLE24TheNorthAmericantreatmentsforsyndromesofdementiaandmovementdisordersmarket size,bysegment,2010–2013(USDmillion) TABLE25TheNorthAmericantreatmentsforsyndromesofdementiaandmovementdisordersmarket size,bysegment,2014–2020(USDmillion) 9 PersistenceMarketResearch

  10. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 TABLE26TheEuropeantreatmentforsyndromesofdementiaandmovementdisordersmarketsize,by country,2010–2013(USDmillion) TABLE27TheEuropeantreatmentforsyndromesofdementiaandmovementdisordersmarketsize,by country,2014–2020(USDmillion) TABLE28TheEuropeantreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,by segment,2010–2013(USDmillion) TABLE29TheEuropeantreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,by segment,2014–2020(USDmillion) TABLE30TheAsiantreatmentforsyndromesofdementiaandmovementdisordersmarketsize,by country,2010–2013(USDmillion) TABLE31TheAsiantreatmentforsyndromesofdementiaandmovementdisordersmarketsize,by country,2014–2020(USDmillion) TABLE32TheAsiantreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,by segment,2010–2013(USDmillion) TABLE33TheAsiantreatmentsforsyndromesofdementiaandmovementdisordersmarketsize,by segment,2014–2020(USDmillion) TABLE34F.Hoffmann-LaRoche,Ltd.’sproductcategories TABLE35Baxter’sproductcategoriesTABLE36 NovartisAG’sproductcategoriesTABLE37 Merck&Co.,Inc.’sproductcategoriesTABLE38 Sanofi’sproductcategories TABLE39Pfizer,Inc.’sproductcategories TABLE40ValeantPharmaceuticalsInternational,Inc.’sproductcategories TABLE41AstraZenecaGmbH’sproductcategories TABLE42AbbottLaboratories,Inc.’sproductcategories TABLE43Bristol-MyersSquibbCompany’sproductcategories ListofFigures FIG.1Treatmentforsyndromesofdementiaandmovementdisorders analysis FIG.2Typesofdementiaandmovementdisorders18 market:Porter’sfiveforces FIG.3Globaltreatmentsforsyndromesofdementiaandmovementdisordersmarketshare,byregion,by value,2013 10 PersistenceMarketResearch

  11. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 FIG.4Globaltreatmentsforsyndromesofdementiaandmovementdisordersmarketshare,bysegment, byvalue,2013 FIG.5Globalprogressivedementiatherapeuticmarketshare,bydisease,byvalue,2013 FIG.6Globalprogressivedementiamarketshare,bydrugcategory,byvalue,2013 FIG.7Globalprogressivedementiawithotherneurologicalabnormalitiestherapeuticsmarketshare,by disease,byvalue,2013 FIG.8Globalprogressivedementiawithotherneurologicalabnormalitiesmarketshare,bydrugcategory, byvalue,2013 FIG.9Globalmovementdisordersyndrometherapeuticsmarketshare,bydisease,byvalue,2013 FIG.10Globalmovementdisordersyndromemarketshare,bydrugcategory,byvalue,2013 FIG.11TheNorthAmericantreatmentforsyndromesofdementiaandmovementdisordersmarketshare, bycountry,byvalue,2013 FIG.12TheNorthAmericantreatmentsforsyndromesofdementiaandmovementdisordersmarket share,bysegment,byvalue,2013 FIG.13TheEuropeantreatmentforsyndromesofdementiaandmovementdisordersmarketshare,by country,byvalue,2013 FIG.14TheEuropeantreatmentsforsyndromesofdementiaandmovementdisordersmarketshare,by segment,byvalue,2013 FIG.15TheAsiantreatmentforsyndromesofdementiaandmovementdisordersmarketshare,by country,byvalue,2013 FIG.16TheAsiantreatmentsforsyndromesofdementiaandmovementdisordersmarketshare,by segment,byvalue,2013 FIG.17Competitivelandscapeoftreatmentprovidersforsyndromesofdementiaandmovement disorders,2013 FIG.18F.Hoffmann-LaRoche,Ltd.’ssalesandnetincome,2011–2013(USDmillion) FIG.19Baxter’snetsalesandnetincome,2011–2013(USDmillion) FIG.20NovartisAG’snetsalesandnetincome,2011–2013(USDmillion) FIG.21Merck&Co.,Inc.’ssalesandnetincome,2011–2013(USDmillion) FIG.22Sanofinetsalesandnetincome,2011–2013(USDmillion) FIG.23Pfizer,Inc.’srevenueandnetincome,2011–2013(USDmillion) FIG.24ValeantPharmaceuticalsInternational,Inc.’srevenuesandnetincome/loss,2011–2013(USD million) FIG.25AstraZenecaGmbH’srevenuesandprofit,2011–2013(USDmillion) FIG.26AbbottLaboratories’netsalesandnetearnings,2011–2013(USDmillion) 11 PersistenceMarketResearch

  12. DementiaandMovementDisordersMarket-GlobalStudyonTreatmentfor SyndromesofDementiaandMovementDisorders:AsiatoWitness HighestGrowthby2020 FIG.27Bristol-MyersSquibb’srevenueandnetearnings,2011–2013(USDmillion) AboutUs: PersistenceMarketResearchisaglobalmarketresearchfirmspecializing-syndicatedresearch,customresearch,andconsultingservices AtPersistenceMarketResearch(PMR),weareinthebusinessofacceleratingyourbusiness.Asafull- servicemarketresearchfirm,westandcommittedtobringingmoreaccuracyandspeedtoyourbusiness decisions.Fromready-to-purchasemarketresearchreportstocustomizedglobalresearchsolutions,our engagementmodelsarehighlyflexiblewithoutcompromisingonourdeep-seatedresearchvalues. Brieflystated,ourmissionistogiveyouaccesstoforecastsandtrendsanalysesthatputyouonthe pathto profitability. PMR’sServicesGoBeyondGleaningData MostenterprisesbelievethatITanddatabasesareenoughtomakeanaccuratedecision.Whilewedo notdisputethat,considerthis:Howlongdoesittaketomakeanaccurate decision?Westrivetodeliverbothevenwithdemandingdeadlines. andstrategicmillion-dollar ContactUs: AddieThomes 305Broadway,7thFloor, NewYorkCity,NY10007, UnitedStates. Tel:No.+1-646-568-77 USA/CanadaTollFreeNumber.1-800-961-0353 E-mail:Sales@persistencemarketresearch.com web:http://www.persistencemarketresearch.com/ 12 PersistenceMarketResearch

More Related